Yazar: Ayalew Tefferi

The discovery of the JAK2 V617F mutation in the majority of patients with bcr/ abl-negative myeloproliferative neoplasms has stimulated a number of questions regarding the diagnosis, prognosis, and treatment of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. This book provides evidence-based reviews and expert consensus results concerning the key clinical issues for patient management. Practical recommendations are provided for the optimization and standardization of management of all three types of myeloproliferative neoplasm. Risk stratification, treatment goals, and first- and second-line therapies are discussed in detail, and other relevant diagnostic and research issues are also addressed. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.